To better understand how CQ influences NIS function, we characterised NIS expression at the PM via cell surface biotinylation assays (CSBA), which demonstrated elevated levels of cell-surface NIS in CQ-treated thyroid cancer cells (Fig. 4D). The gene discussed is SLC5A5; the disease is thyroid gland carcinoma.